Figure 4
Cisplatin chemosensitisation mechanisms after FGF2-targeted Ad-NBS1 gene transfer in vivo. The apoptotic index was determined in the tumour samples. (A) The apoptotic index was found to be significantly higher in Ad-NBS1/Regular cisplatin samples. Tumours treated with Ad-NBS1/Reduced cisplatin exhibited similar levels as those tumours treated with regular dose of cisplatin. (B) The apoptotic index was found to be significantly higher in the all treated groups than in controls. No significant difference was found between treated groups. #P<0.01 when compared with Ad-NBS1/Regular dose of cisplatin, +P<0.01 when compared with Ad-NBS1/Reduced dose of cisplatin, *P<0.01 when compared with FGF2-Ad-NBS1/Reduced dose of cisplatin. (C) Representative CD31 staining figures show significantly less staining in the tumours of FGF2-Ad-NBS1/Reduced cisplatin. (D) A significantly smaller %ROI CD31 staining was observed in FGF2-Ad-NBS1/Reduced cisplatin when compared with control and the other treatment groups. Scale bar: 100 μm; *P<0.01 when compared with FGF2-Ad-NBS1/Reduced cisplatin; **P<0.05 when compared with FGF2-Ad-NBS1/Reduced cisplatin.
